AbbVie and Germany-based DISCO Pharmaceuticals announced a collaboration and option-to-license deal to discover and develop AND-gated bispecific therapies for solid tumors.
DISCO will receive $40 million upfront and could earn up to $2.5 billion in option, development, and other milestone payments, plus tiered royalties on worldwide sales. The deal is described as worth up to about $2.54 billion including the upfront payment.
DISCO will conduct research using its DISCOtech platform to identify pairs of proteins on cancer-cell surfaces. The approach aims to activate treatments when both targets are present, potentially improving tumor selectivity and sparing healthy tissue.
After specified research activities, AbbVie can choose to exclusively license selected programs for further development. The companies have not disclosed the specific targets, number of programs, or clinical timelines; the collaboration is at an early stage.
Sources:
AbbVie expands bispecific cancer med push with up to $2.5 billion deal ...
AbbVie signs cancer drug development deal with up to $2.5B in milestones
Disco Pharma Partners With AbbVie to Develop Bispecific Therapies for Solid Tumors
AbbVie busts a move with Disco in $2.5B dance aimed at bispecific discovery
AbbVie, DISCO Partner On Solid Tumor Therapies; Deal Includes Up ...
AbbVie and Disco ink $2.5bn pact for next-generation cancer bispecifics - Pharmaceutical Technology
AbbVie Targets Solid Tumors in Deal Worth Up to $2.54 Billion
Source: Disco Pharmaceuticals GmbH
AbbVie, Disco Pharmaceuticals Enter Solid Tumor Collaboration, Option-to-License Deal
AbbVie taps DISCO's surfaceome mapping platform in $2.5B deal
AbbVie grooves with DISCO's solid tumor tech in up to $2.5B licensing deal
AbbVie inks up to $2.54B bispecific cancer drug deal with DISCO Pharma
Does AbbVie (ABBV) Need This New Solid Tumor Cancer Partnership?